US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Invitation to presentation of the Q4 Interim Report, on January 27 at 2 pm CET

    Uppsala, Sweden – January 20, 2022 – As previously communicated Orexo will announce the Q4 Interim Report, which also includes the 2021 Full Year Report, on January 27 at 8 am CET. The same day at 2 pm CET analysts, investors and media are invited to attend a presentation where Nikolaj Sørensen, CEO, Joseph DeFeo, CFO and Robert Rönn, Head of R&D will present the latest development. After the presentation a Q&A will be held. Questions can also be sent in advance to ir@orexo.com, not later than 11 am CET.Please view the instructions below on how to participate. Link: https://tv.

    Orexo Q4 2020, incl. Full Year Report

    ZUBSOLV® stable and strong EBIT, despite challenging market due to Covid-19  Q4 2020 highlights · Total net revenues of SEK 159.2 m (238.1 last year, 196.2 m excl. Abstral® EU and US) · Net earnings of SEK -49.6 m (38.9) · EBITDA of SEK 1.0 m (85.8) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 143.1 m (190.5), EBIT of SEK 94.4 m (95.5) · Cash flow from operating activities of SEK -11.2 m (60.2), cash balance of SEK 505.3 m (816.8) · Secured a preferred position for ZUBSOLV® as the only branded product on national commercial and Medicare Part D formularies

    Q4 incl. Full Year Report 2019

    Strong fundamentals in place to fuel strategy for future growth Q4 2019 highlights · Total net revenues of SEK 238.1 million (227.1), up 4.8 percent · Zubsolv® US net revenues of SEK 190.5 million (166.7), up 14.3 percent in SEK and 7.5 percent in local currency · Net earnings of SEK 38.9 million (51.6), down 24.6 percent · EBITDA of SEK 85.8 million (42.8), up 100.5 percent. EBITDA ex Abstral® of SEK 39.6 million (-9.6). · US EBIT of SEK 98.2 million (62.0), up 58,4 percent · Cash flow from operating activities of SEK 60.2 million (71.7), building a cash balance of

    Q4 incl. Full Year Report 2018

    2018 was a pivotal year for Orexo Q4 2018 highlights · Total net revenues of SEK 227.1 million (191.0), up 18.9 percent from Q4 previous year · Zubsolv® US net revenue of SEK 166.7 million (126.5), up 31.8 percent in SEK and 21.3 percent in local currency compared to the same period last year · EBITDA of SEK 42.8 million (35.3), EBITDA excluding IP litigation costs of SEK 69.2 million (43.1) · US EBIT of SEK 62.0 million (19.8) · Cash flow from operating activities of SEK 71.7 million (-23.0), building a cash balance of SEK 589.8 million (327.9) · Earnings per share,

    Full year report January-December 2015

    Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. 2015 – a year of investments and growth. Zubsolv® revenue growth of83 percent. Fourth quarter 2015 ▪      Total net revenues amounted to MSEK 228.3 (220.5). ▪      Zubsolv net revenue amounted to MSEK 120.3 (79.5). ▪      Earnings after tax were MSEK -51.8 (51.6). ▪      Earnings per share were SEK -1.50 (1.50). ▪      Cash flow from operating activities amounted to MSEK 6.3 (-7.3). ▪      Orexo received MGBP 5 milestone payment

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media